Candel Therapeutics (NASDAQ:CADL – Get Free Report) and SOPHiA GENETICS (NASDAQ:SOPH – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, profitability, earnings, analyst recommendations and risk.
Insider & Institutional Ownership
13.9% of Candel Therapeutics shares are owned by institutional investors. Comparatively, 31.6% of SOPHiA GENETICS shares are owned by institutional investors. 41.6% of Candel Therapeutics shares are owned by insiders. Comparatively, 4.9% of SOPHiA GENETICS shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Valuation & Earnings
This table compares Candel Therapeutics and SOPHiA GENETICS”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Candel Therapeutics | $120,000.00 | 1,869.67 | -$37.94 million | ($1.28) | -5.89 |
| SOPHiA GENETICS | $64.94 million | 3.86 | -$78.98 million | ($1.12) | -3.42 |
Volatility and Risk
Candel Therapeutics has a beta of -0.94, indicating that its stock price is 194% less volatile than the S&P 500. Comparatively, SOPHiA GENETICS has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current recommendations for Candel Therapeutics and SOPHiA GENETICS, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Candel Therapeutics | 0 | 0 | 1 | 0 | 3.00 |
| SOPHiA GENETICS | 0 | 1 | 3 | 0 | 2.75 |
Candel Therapeutics presently has a consensus target price of $11.00, indicating a potential upside of 45.89%. SOPHiA GENETICS has a consensus target price of $6.50, indicating a potential upside of 69.71%. Given SOPHiA GENETICS’s higher probable upside, analysts plainly believe SOPHiA GENETICS is more favorable than Candel Therapeutics.
Profitability
This table compares Candel Therapeutics and SOPHiA GENETICS’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Candel Therapeutics | N/A | -629.29% | -134.23% |
| SOPHiA GENETICS | -102.84% | -47.40% | -34.54% |
Summary
SOPHiA GENETICS beats Candel Therapeutics on 9 of the 14 factors compared between the two stocks.
About Candel Therapeutics
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.
About SOPHiA GENETICS
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.
Receive News & Ratings for Candel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Candel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
